ES2560215T3 - Compuestos para la supresión de un trastorno de los nervios periféricos provocado por un agente anticanceroso - Google Patents

Compuestos para la supresión de un trastorno de los nervios periféricos provocado por un agente anticanceroso Download PDF

Info

Publication number
ES2560215T3
ES2560215T3 ES11705047.6T ES11705047T ES2560215T3 ES 2560215 T3 ES2560215 T3 ES 2560215T3 ES 11705047 T ES11705047 T ES 11705047T ES 2560215 T3 ES2560215 T3 ES 2560215T3
Authority
ES
Spain
Prior art keywords
compound
use according
anticancer agent
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11705047.6T
Other languages
English (en)
Spanish (es)
Inventor
Naomi Kitamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2560215(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2560215T3 publication Critical patent/ES2560215T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES11705047.6T 2010-01-27 2011-01-26 Compuestos para la supresión de un trastorno de los nervios periféricos provocado por un agente anticanceroso Active ES2560215T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27
JP2010015935 2010-01-27
PCT/JP2011/052077 WO2011093512A1 (en) 2010-01-27 2011-01-26 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Publications (1)

Publication Number Publication Date
ES2560215T3 true ES2560215T3 (es) 2016-02-17

Family

ID=43770309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11705047.6T Active ES2560215T3 (es) 2010-01-27 2011-01-26 Compuestos para la supresión de un trastorno de los nervios periféricos provocado por un agente anticanceroso

Country Status (41)

Country Link
US (5) US20130046000A1 (enExample)
EP (1) EP2528598B1 (enExample)
JP (2) JP6131046B2 (enExample)
KR (1) KR20120118044A (enExample)
CN (2) CN104744321A (enExample)
AR (1) AR080024A1 (enExample)
AU (1) AU2011211294B2 (enExample)
BR (1) BR112012018434A2 (enExample)
CA (1) CA2788150C (enExample)
CL (1) CL2012002079A1 (enExample)
CO (1) CO6592110A2 (enExample)
CR (1) CR20120412A (enExample)
CY (1) CY1117268T1 (enExample)
DK (1) DK2528598T3 (enExample)
DO (1) DOP2012000209A (enExample)
EA (1) EA201290697A1 (enExample)
EC (1) ECSP12012126A (enExample)
ES (1) ES2560215T3 (enExample)
GE (1) GEP20166441B (enExample)
HR (1) HRP20160165T1 (enExample)
HU (1) HUE027310T2 (enExample)
IL (1) IL221066A (enExample)
MA (1) MA34014B1 (enExample)
ME (1) ME02364B (enExample)
MX (1) MX2012008514A (enExample)
MY (1) MY163936A (enExample)
NZ (1) NZ601635A (enExample)
PE (1) PE20121694A1 (enExample)
PH (1) PH12012501538A1 (enExample)
PL (1) PL2528598T3 (enExample)
PT (1) PT2528598E (enExample)
RS (1) RS54591B1 (enExample)
SG (2) SG10201503402XA (enExample)
SI (1) SI2528598T1 (enExample)
SM (1) SMT201600103B (enExample)
TN (1) TN2012000364A1 (enExample)
TW (1) TWI481401B (enExample)
UA (1) UA109540C2 (enExample)
UY (1) UY33203A (enExample)
WO (1) WO2011093512A1 (enExample)
ZA (1) ZA201205681B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150013143A (ko) * 2012-04-27 2015-02-04 니폰 조키 세야쿠 가부시키가이샤 트랜스-2-데센산 유도체 및 이것을 함유하는 의약
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US9611244B2 (en) 2015-05-08 2017-04-04 Takeda Pharmaceutical Company Limited Cyclic compounds
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
WO2019047812A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
WO2021012138A1 (zh) 2019-07-22 2021-01-28 广州英赛特生物技术有限公司 二氨基胍衍生物及其饲用组合物在制备兽医用药物中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
EP0252146B1 (en) 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Method of inducible gene expression
WO1989007614A1 (en) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE68910682T2 (de) 1988-03-01 1994-06-01 Whitehead Biomedical Inst Aktivierung der nf-kappa b-vorstufe.
AU5419690A (en) 1989-03-31 1990-11-05 Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
EP0557290A1 (en) 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
ES2134804T3 (es) 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
KR19990022369A (ko) * 1995-06-07 1999-03-25 스테판 이반스-프레크 어뎁터 단백질/티로신 카이나제 상호작용을 방해하는 조성물과그 방법
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
WO2001090151A2 (en) 2000-05-25 2001-11-29 Schering Corporation Human receptor proteins; related reagents and methods
AU1070399A (en) 1997-10-17 1999-05-10 Genentech Inc. Human toll homologues
ZA989147B (en) 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
AU1539499A (en) 1997-11-25 1999-06-15 Princeton University Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
DK1063228T5 (da) 1998-03-09 2009-06-15 Takeda Pharmaceutical Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
WO2001010826A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. Substituted aromatic-ring compounds, process for producing the same, and use
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
CA2685447C (en) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
KR100821546B1 (ko) 2000-10-18 2008-04-11 다케다 야쿠힌 고교 가부시키가이샤 광학 활성 술폰아미드의 제조 방법 및 그의 합성용 중간체
WO2002045470A1 (fr) 2000-11-30 2002-06-06 Tokuyama Corporation Substrat et procede de production correspondant
AU2002221099A1 (en) 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
JP5137289B2 (ja) 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
EP1495756A4 (en) * 2002-04-08 2009-10-28 Takeda Pharmaceutical THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040259790A1 (en) 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
EP1613956A2 (en) 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
EP1664342A4 (en) 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
JP5040650B2 (ja) 2005-06-03 2012-10-03 小野薬品工業株式会社 神経再生および／または保護剤
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007091790A1 (en) 2006-02-07 2007-08-16 Korea Institute Of Radiological & Medical Sciences A composition for treating damage of central or peripheral nerve system
ATE524732T1 (de) 2006-02-23 2011-09-15 Univ Yale Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
EP1997902B1 (en) 2006-03-30 2013-09-18 Hiroshima University Screening method
JPWO2007123186A1 (ja) 2006-04-20 2009-09-03 武田薬品工業株式会社 医薬
JPWO2007132825A1 (ja) 2006-05-15 2009-09-24 武田薬品工業株式会社 医薬
US20090209585A1 (en) 2006-07-07 2009-08-20 Takashi Ichikawa Cycloalkene derivatives, process for production of the derivatives, and use of the same
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en) 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
EP2480536B1 (en) 2009-09-23 2014-08-13 The Regents of the University of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof

Also Published As

Publication number Publication date
UA109540C2 (uk) 2015-09-10
SG182522A1 (en) 2012-08-30
ZA201205681B (en) 2013-09-25
DK2528598T3 (en) 2016-03-07
CA2788150A1 (en) 2011-08-04
KR20120118044A (ko) 2012-10-25
US20160166526A1 (en) 2016-06-16
AU2011211294A2 (en) 2012-10-04
NZ601635A (en) 2013-06-28
AU2011211294B2 (en) 2014-11-13
PH12012501538A1 (en) 2015-11-09
HRP20160165T1 (hr) 2016-03-11
SMT201600103B (it) 2016-04-29
PT2528598E (pt) 2016-03-04
ECSP12012126A (es) 2012-09-28
MX2012008514A (es) 2012-08-17
EA201290697A1 (ru) 2013-02-28
US8901171B2 (en) 2014-12-02
JP6131046B2 (ja) 2017-05-17
AU2011211294A1 (en) 2012-09-20
DOP2012000209A (es) 2012-12-31
PL2528598T3 (pl) 2016-06-30
CR20120412A (es) 2012-11-13
CO6592110A2 (es) 2013-01-02
CY1117268T1 (el) 2017-04-26
WO2011093512A1 (en) 2011-08-04
SG10201503402XA (en) 2015-06-29
US20150051256A1 (en) 2015-02-19
JP2016175903A (ja) 2016-10-06
US20130345304A1 (en) 2013-12-26
US20130046000A1 (en) 2013-02-21
CA2788150C (en) 2017-06-06
EP2528598A1 (en) 2012-12-05
BR112012018434A2 (pt) 2016-04-19
MA34014B1 (fr) 2013-02-01
GEP20166441B (en) 2016-03-10
PE20121694A1 (es) 2012-12-06
TN2012000364A1 (en) 2014-01-30
TW201130482A (en) 2011-09-16
IL221066A (en) 2016-10-31
JP2013518032A (ja) 2013-05-20
US20150203464A1 (en) 2015-07-23
CN102821763A (zh) 2012-12-12
CL2012002079A1 (es) 2012-12-21
HUE027310T2 (en) 2016-10-28
SI2528598T1 (sl) 2016-04-29
AR080024A1 (es) 2012-03-07
HK1177423A1 (zh) 2013-08-23
RS54591B1 (sr) 2016-08-31
UY33203A (es) 2011-08-31
EP2528598B1 (en) 2016-01-13
MY163936A (en) 2017-11-15
TWI481401B (zh) 2015-04-21
ME02364B (me) 2016-06-20
CN102821763B (zh) 2017-09-22
CN104744321A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
ES2965675T3 (es) Antagonistas del receptor NK-3 para el tratamiento terapéutico o cosmético del exceso de grasa corporal
DK2528598T3 (en) RELATIONS TO suppress PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
JP6462045B2 (ja) スルフォラファンの単離及び精製
ES2784703T3 (es) Derivados de la pirrolidina carboxamida y métodos para preparar y utilizar la misma
KR20170125951A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
ES2886935T3 (es) Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
US20210196730A1 (en) Compound and use thereof
JP2019034977A (ja) 癌を処置するための新規方法
WO2019084300A1 (en) TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS
CA3224544A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
ES2725893T3 (es) Composiciones enriquecidas con S-enantiómeros de betabloqueantes para tratar la esclerosis lateral amiotrófica
ES2952834T3 (es) Lipoil-Glu-Ala para el tratamiento de daño neurodegenerativo producido por traumatismo craneoencefálico
CN121127460A (zh) 可用作治疗剂的新型化合物
CN114929335A (zh) RORγt抑制剂及其局部用途
HK1177423B (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent